3.0
18 Mar 2016
Recommend
CEO approval
Business outlook
Pros
Excellent technical and animal resources. Excellent clinical research infrastructure. Possibility of many collaborations internally. General funding stability although rapidly loosing purchasing power due to inflation.
Cons
Poor institute level management in the Center for Cancer Research (intra-mural NIH). Complete lack of vision. Attitude of maintaining status quo even for underperforming research and clinical groups. Underutilized clinical center. Rapid loss of a critical mass of physician-scientists to the extramural community in recent years.